超声造影定位乳腺癌腋窝前哨淋巴结的前瞻性研究
该前瞻性研究纳入143例早期乳腺癌患者,评估超声造影(CEUS)定位腋窝前哨淋巴结(SLN)的价值。CEUS识别SLN率为84.0%(121/144),双标记法为97.92%(141/144);CEUS-SLN联合细针穿刺细胞学(FNAC)诊断转移的敏感度78.38%、特异度100%。结论认为CEUS是定位SLN有前景的方法,但单独CEUS难以识别淋巴结转移。
要点
- CEUS识别SLN率为84.0%(121/144),低于双标记法的97.92%(141/144)。
- CEUS-SLN联合FNAC诊断转移的敏感度78.38%、特异度100%。
- 淋巴结未增强(p=0.060)或增强不均匀(p=0.468)与转移无显著关联。
关键影像表现/征象
- CEUS识别SLN率为84.0%(121/144),双标记法为97.92%(141/144)。
- 淋巴结未增强(p=0.060)或增强不均匀(p=0.468)与淋巴结转移无显著关联。
诊断标准与关键数值
- CEUS-SLN联合FNAC诊断转移的敏感度为78.38%,特异度为100%。
临床应用与阅片要点
- CEUS可用于术前定位腋窝SLN,但单独CEUS难以判断淋巴结是否转移。
- CEUS定位的SLN联合FNAC可提高术前诊断SLN转移的准确性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The objective was to explore the clinical value of contrast-enhanced ultrasound (CEUS) in locating the sentinel lymph node (SLN) in patients with early breast cancer. We screened 143 consecutive patients with breast cancer between July 2017 and August 2019. The number of SLNs identified by CEUS and dual labeling (blue dye and radiolabeled colloid) were recorded. The accuracy of CEUS plus fine-needle aspiration cytology (FNAC) was assessed. The rate of identification of SLNs with CEUS was 84.0% (121/144), and that of dual labeling was 97.92% (141/144). There was no significant association between non-enhancement (p = 0.060) or inhomogeneous enhancement (p = 0.468) and lymph node metastasis. The sensitivity and specificity of CEUS-SLNs plus FNAC was 78.38% and 100%, respectively. The technique of CEUS is a promising method for locating the axillary SLN. But it is hard to identify lymph node metastasis with CEUS alone. CEUS-SLNs plus FNAC is a sound technique for diagnosis of the metastasis of SLN.
引用
- Liu YB, Xia M, Li YJ, et al. Contrast-Enhanced Ultrasound in Locating Axillary Sentinel Lymph Nodes in Patients with Breast Cancer: A Prospective Study. Ultrasound Med Biol. 2021. PMID: 33714619. doi:10.1016/j.ultrasmedbio.2021.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。